NYSE - Nasdaq Real Time Price USD

Pfizer Inc. (PFE)

Compare
24.94 -0.16 (-0.64%)
At close: November 20 at 4:00 PM EST
24.88 -0.06 (-0.24%)
Pre-Market: 4:31 AM EST
Loading Chart for PFE
DELL
  • Previous Close 25.10
  • Open 25.07
  • Bid --
  • Ask --
  • Day's Range 24.65 - 25.10
  • 52 Week Range 24.48 - 31.54
  • Volume 40,569,908
  • Avg. Volume 36,462,682
  • Market Cap (intraday) 141.335B
  • Beta (5Y Monthly) 0.62
  • PE Ratio (TTM) 33.25
  • EPS (TTM) 0.75
  • Earnings Date Jan 28, 2025 - Feb 3, 2025
  • Forward Dividend & Yield 1.68 (6.74%)
  • Ex-Dividend Date Nov 8, 2024
  • 1y Target Est 32.55

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

www.pfizer.com

88,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: PFE

View More

Performance Overview: PFE

Trailing total returns as of 11/20/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

PFE
8.08%
S&P 500
24.05%

1-Year Return

PFE
11.55%
S&P 500
31.08%

3-Year Return

PFE
43.77%
S&P 500
25.95%

5-Year Return

PFE
13.54%
S&P 500
89.64%

Compare To: PFE

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: PFE

View More

Valuation Measures

Annual
As of 11/20/2024
  • Market Cap

    141.33B

  • Enterprise Value

    198.00B

  • Trailing P/E

    33.25

  • Forward P/E

    8.37

  • PEG Ratio (5yr expected)

    0.18

  • Price/Sales (ttm)

    2.38

  • Price/Book (mrq)

    1.53

  • Enterprise Value/Revenue

    3.33

  • Enterprise Value/EBITDA

    14.31

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    7.16%

  • Return on Assets (ttm)

    3.31%

  • Return on Equity (ttm)

    4.54%

  • Revenue (ttm)

    59.38B

  • Net Income Avi to Common (ttm)

    4.27B

  • Diluted EPS (ttm)

    0.75

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    9.95B

  • Total Debt/Equity (mrq)

    73.41%

  • Levered Free Cash Flow (ttm)

    11.42B

Research Analysis: PFE

View More

Company Insights: PFE

Research Reports: PFE

View More

People Also Watch